Aurobindo Pharma Limited expects injectables’ revenues to increase to $650-700m over three years from the current $380m with contribution from Europe and emerging markets growing even as injectable margins in the US see a possible decline due to increased competition.
A new plant in Vizag is expected to be commissioned in around a year, with supply directed to Europe and...